APOE and atherosclerosis: Recently, we demonstrated that activation of FFAR4 by its agonist, TUG-891, inhibited atherosclerosis in mice with knockout of apolipoprotein E (apoE−/−mice), which was associated with a beneficial phenotypical change between M1/M2 macrophages in atherosclerotic plaques [5].